Oncolytic Virus-Driven Biotherapies from Bench to Bedside
- PMID: 36879416
- DOI: 10.1002/smll.202206948
Oncolytic Virus-Driven Biotherapies from Bench to Bedside
Abstract
With advances in cancer biology and an ever-deepening understanding of molecular virology, oncolytic virus (OV)-driven therapies have developed rapidly and become a promising alternative to traditional cancer therapies. In recent years, satisfactory results for oncolytic virus therapy (OVT) are achieved at both the cellular and organismal levels, and efforts are being increasingly directed toward clinical trials. Unfortunately, OVT remains ineffective in these trials, especially when performed using only a single OV reagent. In contrast, integrated approaches, such as using immunotherapy, chemotherapy, or radiotherapy, alongside OVT have demonstrated considerable efficacy. The challenges of OVT in clinical efficacy include the restricted scope of intratumoral injections and poor targeting of intravenous administration. Further optimization of OVT delivery is needed before OVs become a viable therapy for tumor treatment. In this review, the development process and antitumor mechanisms of OVs are introduced. The advances in OVT delivery routes to provide perspectives and directions for the improvement of OVT delivery are highlighted. This review also discusses the advantages and limitations of OVT monotherapy and combination therapy through the lens of recent clinical trials and aims to chart a course toward safer and more effective OVT strategies.
Keywords: antitumor mechanisms; clinical trials; intravenous administration; oncolytic viruses; traditional cancer therapies.
© 2023 Wiley-VCH GmbH.
Similar articles
-
Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy.Nano Res. 2022;15(5):4137-4153. doi: 10.1007/s12274-021-4031-6. Epub 2022 Feb 14. Nano Res. 2022. PMID: 35194488 Free PMC article. Review.
-
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.J Transl Med. 2023 Jul 25;21(1):500. doi: 10.1186/s12967-023-04360-8. J Transl Med. 2023. PMID: 37491263 Free PMC article. Review.
-
Development of oncolytic virotherapy: from genetic modification to combination therapy.Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7. Front Med. 2020. PMID: 32146606 Free PMC article. Review.
-
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Front Immunol. 2021 Oct 5;12:721830. doi: 10.3389/fimmu.2021.721830. eCollection 2021. Front Immunol. 2021. PMID: 34675919 Free PMC article. Review.
-
Improving systemic delivery of oncolytic virus by cellular carriers.Cancer Biol Med. 2025 Jan 17;21(12):1104-19. doi: 10.20892/j.issn.2095-3941.2024.0390. Cancer Biol Med. 2025. PMID: 39831754 Free PMC article. Review.
Cited by
-
Oncolytic vaccinia virus and cancer immunotherapy.Front Immunol. 2024 Jan 12;14:1324744. doi: 10.3389/fimmu.2023.1324744. eCollection 2023. Front Immunol. 2024. PMID: 38283361 Free PMC article. Review.
-
Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.Genes (Basel). 2024 Sep 11;15(9):1193. doi: 10.3390/genes15091193. Genes (Basel). 2024. PMID: 39336785 Free PMC article. Review.
-
cJun-N-terminal kinase activity and mitosis perturbation drive the 2-methoxyestradiol-mediated enhancement of viral oncolysis by Epizootic Hemorrhagic Disease Virus-Tel Aviv University.Sci Rep. 2025 Jul 9;15(1):24624. doi: 10.1038/s41598-025-08687-8. Sci Rep. 2025. PMID: 40634455 Free PMC article.
-
Optimizing Oncolytic Virotherapy for Malignant Glioma: From Bench to Bedside.Cancer Manag Res. 2025 Aug 4;17:1537-1554. doi: 10.2147/CMAR.S528875. eCollection 2025. Cancer Manag Res. 2025. PMID: 40786912 Free PMC article. Review.
-
PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression.Viruses. 2023 May 11;15(5):1153. doi: 10.3390/v15051153. Viruses. 2023. PMID: 37243239 Free PMC article.
References
-
- R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, CA Cancer J. Clin. 2021, 71, 7.
-
- M. G. Lizio, R. Boitor, I. Notingher, Analyst 2021, 146, 3799.
-
- C. Y. Chen, Y. S. Lin, C. H. Chen, Y. J. Chen, J. Biomed. Sci. 2018, 25, 30.
-
- H. L. Kaufman, F. J. Kohlhapp, A. Zloza, Nat. Rev. Drug Discovery 2015, 14, 642.
-
- A. H. Choi, M. P. O'Leary, Y. Fong, N. G. Chen, Biomedicines 2016, 4, 18.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical